Krystal Biotech (KRYS) Net Margin (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly Net Margin of 45.94% for Q2 2026, up 603.0% year-over-year from 6.53% in Q2 2025, and down 4.4% on a QoQ basis from 48.05% in Q1 2026.
Powered by 
Analysis
Krystal Biotech (KRYS) Net Margin (2023 - 2026) Analysis & Trends
Krystal Biotech has reported Net Margin for 4 years, with the latest figure at 45.94% in Q2 2026.
- Net Margin for Q2 2026 came in at 45.94%, up 603.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 54.81% (up 1397.0% YoY), and the FY2025 annual result was 52.64%, up 2195.0% from the prior year.
- Net Margin slipped to 45.94% in Q2 2026, from 48.05% in the prior quarter.
- Over five years, Net Margin peaked at 943.75% in Q3 2023 and troughed at 2.06% in Q1 2024.
- A 4-year average of 114.54% and a median of 43.21% in 2026 frame the typical range for Net Margin.
- The widest annual swing landed in 2024, when Net Margin sank 91134 bps; it then surged 4875 bps in 2025.
- A 4-year view of Net Margin shows it stood at 20.62% in 2023, then surged by 142 bps to 49.95% in 2024, then retreated by 4 bps to 47.98% in 2025, then slipped by 4 bps to 45.94% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 45.94% in Q2 2026, 48.05% in Q1 2026, and 47.98% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | 45.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.94% |
| Mar 31, 2026 | 48.05% |
| Dec 31, 2025 | 47.98% |
| Sep 30, 2025 | 81.15% |
| Jun 30, 2025 | 39.91% |
| Mar 31, 2025 | 40.47% |
| Dec 31, 2024 | 49.95% |
| Sep 30, 2024 | 32.41% |
| Jun 30, 2024 | 22.15% |
| Mar 31, 2024 | 2.06% |
| Dec 31, 2023 | 20.62% |
| Sep 30, 2023 | 943.75% |